Post by Monte Rosa Therapeutics

Important piece in Nature Medicine from Charlotte Harrison about the growing recognition of inflammation as a key driver of cardiovascular disease.   The science is increasingly clear: inflammation is not simply a consequence of cardiovascular disease, it is a fundamental cause. Yet it remains inadequately addressed for many patients.   CMO Filip Janku discusses why we believe molecular glue degraders represent a differentiated approach to targeting inflammation. By acting upstream in the NLRP3 inflammasome pathway, our NEK7-directed MGD, MRT-8102, has the potential to interrupt the inflammatory cascade at its source.   Read more: https://bit.ly/4aiA9gE